Cervical infection is a serious infectious disease that is clinically common and can be caused by a variety of pathogens, including the Grelanella vaginal bacteria, the Grelanne positive bacteria and the anaerobic bacteria. The complexity and variability of their condition not only makes it difficult to control infection if antibacterial drugs are not used properly, but may also lead to serious consequences, such as bacterial resistance, failure of treatment and poor patient prognosis. Therefore, a reasonable choice of antibacterial drugs is a key element in the treatment of abdominal infections.
(a) Common pathogens with abdominal infections. In general, the gland vaginal fungus is the main pathogens of abdominal infections, such as coli-Eshi, creber, intestinal coli. These bacteria are infested in the intestinal tract and can enter the abdominal cavity to cause infection when there is a change in the internal cavity, such as intestinal piercing, rupture, etc. Geran positive bacteria, such as yellow grapes and intestinal fungus, can also be involved in abdominal infections, especially in trauma or post-operative infections. In addition, anaerobics also occupy an important position in abdominal infections, with the common occurrence of VC, and SCI. Anaerobics and aerobics are often co-infected, and the toxins and enzymes they produce can exacerbate tissue damage and increase the complexity and curableness of the infection.
II. Principles for the selection of antibacterial drugs (i) Coverage of pathogen spectrophytes Based on the diversity of common pathogens of abdominal infections, antibacterial drugs should be selected with a wide spectrum of antibacterial activity, capable of covering both the grelanella vaginal bacteria, the greland positive bacteria and the anaerobic bacteria. For example, third-generation septactin (e.g., thalamus) has a strong antibacterial effect on the gerland cactus, but the coverage of anaerobics is inadequate, often requiring a combination of nitromics (e.g., thalamus) to compensate for the lack of anaerobic antibacterial spectrogen. In contrast, carbon pyroacneacne (e.g., in the United States of America) has a wider antibacterial spectrum, with good antibacterial activity for various grelanes, grelans positives and anaerobics, and can be one of the first drugs for empirical treatment in cases of severe abdominal infections or in cases where pathogens are unknown. (ii) Different distributions, metabolisms and excretion processes within the abdomen of different antibacterial drugs, which directly affect their antibacterial efficacy, taking into account their pharmacological and pharmacological characteristics. For example, the concentrations of β-neamide antibiotics in the abdominal tissue were similar to those of blood drugs, while the concentrations of amino sugar-like drugs in the abdominal cavity were relatively low. Therefore, the choice of antibacterial drugs needs to be combined with their pharmaceutical-dynamic properties to ensure that the drugs are able to achieve effective fungicide concentrations in the abdominal tract and maintain for sufficient time. In pharmacological terms, time-dependent antibacterial drugs (e.g. β-neamide) need to be kept above the lowest antibacterial concentration (MIC) for a certain period of time, while concentrations of dependent antibacterial drugs (e.g. amino sugar slurry) need to reach a high peak to achieve optimal antibacterial effects. Based on these characteristics, the rational development of the dose, interval and course of treatment of the drug is essential to increase the effectiveness of antibacterial treatment. (iii) The choice and use of anti-bacterial drugs is also significantly influenced by the combination of individual factors, such as the age of the patient, underlying illness, liver and kidney function and immune function. The reduction in liver and kidney function of older patients, the reduction in drug metabolism and excretion capacity, the vulnerability to drug accumulation and adverse effects, the need for appropriate dose adjustments in the selection of antibacterial drugs, and the close monitoring of liver and kidney functions. In cases where the combined liver and kidney function is incomplete, the use of a drug with significant liver and kidney impairment should be avoided or the dose and spacing of the drug should be adjusted to the liver and kidney function indicator. In addition, pathogens infected by people with low immune functions (e.g. tumour chemotherapy patients, AIDS patients, etc.) may be more complex and resistant, and treatment will require the choice of more effective, broad-scale antibacterial drugs and enhanced support for treatment.
In the initial stage of treatment for abdominal infections, experimental antibacterial treatment is often required on the basis of clinical performance of the patient, the source of the infection and local pathogen epidemiology information, as the pathogen is not yet known. For the community ‘ s access to mild and moderate abdominal infections, the choice may be made for a combination of nitromazole-type drugs in the form of head septoxin (e.g., fenthion) or a combination of quinone (e.g., left-oxen fluoride)-type drugs. These programmes have some coverage of common abdominal infections and are relatively safe. In the case of hospital access to sexual abdominal infections or to acute community access to abdominal infections, in view of the potential resistance of pathogen bacteria, empirical treatments often use the combinations of carbon pyroacylene (e.g., amphetamine) or β-nitromide inhibitors (e.g., Zolasilin/Tazabatan). These combinations of drugs have greater antibacterial activity and a wider antibacterial spectrum that can respond effectively to multiple antibacterial infections.
Targeted antibacterial drug treatment, once the results of pathogen culture and drug sensitivity tests have been obtained, should be adapted in a timely manner to implement targeted treatment. The choice of antibacterial drugs that are sensitive to pathogen bacteria and that are clinically effective, based on the results of drug sensitivity trials, can increase the responsiveness and effectiveness of treatment and reduce the risk of unwanted adverse drug reactions and bacterial resistance. For example, if the pharmacological test shows that the pathogen is sensitive to the migraines, the initial empirical treatment programme can be adjusted to a monopharmaceutical treatment; if the fungus is methyloxysilin-resistant, the treatment of MRSA-effective drugs, such as vancomicin or Linazine, is selected.
The choice of anti-bacterial drugs for abdominal infections is a complex and systematic process that requires a combination of information on various types of pathogens, drug characteristics, individual factors of the patient, etc. In clinical practice, antibacterial drugs should be used in accordance with the principle of rational use of antibacterial drugs, based on a combination of empirical and targeted treatment strategies, with a view to improving the curing rate of abdominal infections, improving the prognosis of patients and reducing the incidence and spread of bacterial resistance.
